Luye Pharma Group Ltd. (LYPHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Luye Pharma Group Ltd. (LYPHF) trades at $0.20 with AI Score 49/100 (Grade C). Luye Pharma Group Ltd. Market cap: $815.28M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for LYPHF: LYPHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LYPHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LYPHF: the 1 perspectives are evenly split.
How is this calculated? →Luye Pharma Group Ltd. (LYPHF) Healthcare & Pipeline Overview
Luye Pharma Group Ltd. is a global pharmaceutical entity specializing in the development, manufacturing, and commercialization of a broad portfolio of drugs across oncology, CNS, pain management, and metabolic disorders. Headquartered in China, the company leverages its diverse product pipeline and worldwide distribution network to address various medical needs.
What Is the Investment Thesis for LYPHF?
Luye Pharma Group Ltd. presents a research focus on its diversified pharmaceutical portfolio and global market presence. With a market capitalization of $815.28M and a gross margin of 66.0%, the company demonstrates strong operational efficiency in its core business. The profit margin of 9.8% indicates profitability, although a negative Free Cash Flow (FCF) of $-1.11 billion suggests significant investment in R&D or expansion activities. Key value drivers include the company's extensive product pipeline across high-demand therapeutic areas such as oncology, CNS disorders, and pain management, which could drive future revenue growth. The ongoing development and global distribution of both pharmaceutical and biopharmaceutical products represent potential catalysts for market expansion and increased sales. However, the company's OTC listing and 'Unknown' disclosure status introduce additional risk factors for investors, necessitating thorough due diligence. The beta of 0.92 suggests a volatility profile generally in line with the broader market.
Based on FMP financials and quantitative analysis
LYPHF Key Highlights
- Market capitalization stands at $1.31 billion, reflecting the company's overall valuation in the market.
- Gross margin of 66.0% indicates strong profitability from product sales before operating expenses.
- Profit margin of 9.8% demonstrates the company's ability to convert revenue into net income.
- Free Cash Flow (FCF) is reported at $-1.11 billion, suggesting substantial capital allocation for growth or operational needs.
- The company employs 5150 individuals, highlighting its operational scale and human capital investment.
Who Are LYPHF's Competitors?
LYPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| HAWPF Haw Par Corporation Limited | $12.00 | +0.00% | $2.66B | 49 |
| HAWPY Haw Par Corporation Limited | $54.44 | +1.76% | $3.01B | 50 |
| CHJTF CSPC Pharmaceutical Group Limited | $0.98 | +0.00% | $11.18B | 50 |
| BMYMP Bristol-Myers Squibb Company PFD CONV 2 | $400.00 | -57.46% | $814.59B | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LYPHF's Key Strengths?
- Extensive and diversified product portfolio across multiple therapeutic areas (oncology, CNS, pain, metabolic).
- Global presence with capabilities in development, production, marketing, and sales worldwide.
- Strong gross margin of 66.0% indicates efficient production and pricing power.
- Established company with a founding year of 1994, suggesting operational experience and market understanding.
What Are LYPHF's Weaknesses?
- Negative Free Cash Flow of $-1.11 billion, indicating significant cash outflows or investment needs.
- OTC market listing and 'Unknown' disclosure status may limit investor confidence and market access.
- Reliance on a broad portfolio may dilute focus compared to highly specialized competitors.
- Lack of specific information on R&D pipeline stages or upcoming product launches in the provided data.
What Could Drive LYPHF Stock Higher?
- **Ongoing: Global Market Penetration**: Luye Pharma's continued efforts to market and sell pharmaceutical products worldwide, as stated in its business description, represents an ongoing catalyst for revenue growth and market share expansion in various therapeutic areas.
- **Ongoing: Biopharmaceutical Product Development**: The company's active involvement in manufacturing and selling biopharmaceutical products suggests ongoing research and development in this high-growth sector, which could lead to future product launches and increased market presence.
- **Ongoing: Diversification of Therapeutic Offerings**: The broad range of products across oncology, CNS, pain management, and metabolic disorders indicates an ongoing strategy to diversify revenue streams and address multiple significant medical needs globally, reducing reliance on any single product category.
What Are the Key Risks for LYPHF?
- Financial-distress signal — its Altman Z-Score of 1.36 sits in the distress zone (elevated bankruptcy risk).
- **Potential: Regulatory and Approval Risks**: As a pharmaceutical company, Luye Pharma faces inherent risks associated with stringent regulatory approval processes for new drugs and potential changes in healthcare regulations in various global markets.
- **Ongoing: Competitive Market Landscape**: The 'Drug Manufacturers - General' industry is highly competitive, with numerous established players and new entrants, posing ongoing challenges to market share and pricing power for Luye Pharma's products.
- **Potential: Product Pipeline Dependence**: The company's future growth is dependent on the successful development, approval, and commercialization of new products, with R&D failures or delays posing a significant risk.
- **Ongoing: OTC Market Trading Risks**: The company's listing on the 'OTC Other' tier, coupled with an 'Unknown' disclosure status, presents ongoing risks related to limited liquidity, potential price volatility, and reduced transparency for investors.
- **Ongoing: Negative Free Cash Flow**: A reported Free Cash Flow of $-1.11 billion indicates that the company is currently consuming cash, which, if sustained without corresponding revenue growth, could pose long-term financial risks.
What Are the Growth Opportunities for LYPHF?
- **Expansion in Oncology Therapeutics**: Luye Pharma maintains a robust oncology portfolio, including treatments like Lipusu for ovarian and breast cancer, Tiandida for lung cancer, and Boyounuo for various solid tumors. The global oncology market is projected to grow significantly, driven by increasing cancer incidence and ongoing advancements in treatment modalities. Luye's established presence in this critical area provides a foundation for expanding indications for existing drugs, developing novel compounds, and enhancing market penetration, particularly in regions with rising healthcare expenditure and demand for advanced cancer therapies.
- **Advancement in Central Nervous System (CNS) Disorders**: The company's offerings for CNS conditions, such as the Rivastigmine Transdermal Patch for Alzheimer's disease and Seroquel/Seroquel XR for schizophrenia and bipolar disorders, target a substantial and growing patient population. Neurodegenerative and psychiatric disorders represent areas with significant unmet medical needs and high global prevalence. Continued investment in R&D for new CNS therapies, improved drug delivery systems, and strategic market expansion for these specialized products could unlock considerable growth potential in a market driven by an aging demographic and increased disease awareness.
- **Pain Management Solutions through Transdermal Patches**: Luye Pharma's Fentanyl and Buprenorphine Transdermal Patches address chronic and cancer pain, leveraging a specialized drug delivery method. The pain management market is consistently large, influenced by an aging population and the need for effective, long-acting, and patient-compliant solutions. Expanding the transdermal patch technology to new compounds or indications, and optimizing the existing portfolio for broader market access, could capitalize on the demand for convenient and sustained pain relief options, differentiating the company in a competitive segment.
- **Development in Metabolic and Cardiovascular Health**: With products like Xuezhikang for hypercholesterolaemia and Beixi/Beitangning for Type 2 diabetes, Luye Pharma is positioned within the metabolic and cardiovascular disease markets. These conditions are highly prevalent globally, fueled by lifestyle changes and demographic shifts, leading to a continuous demand for effective treatments. Further development of innovative therapies, lifecycle management of existing products, and strategic market penetration in this therapeutic area can tap into a consistently large patient base requiring long-term management, contributing to sustained revenue streams.
- **Strategic Investment in Biopharmaceutical Products**: The company's involvement in the manufacturing and sale of biopharmaceutical products represents a significant growth avenue. The biopharmaceutical sector is a high-growth segment within healthcare, characterized by innovative therapies, often targeting complex diseases with higher efficacy and specificity. Continued investment in biopharmaceutical research and development, expanding manufacturing capabilities, and securing regulatory approvals for novel biologics could position Luye Pharma to capture a larger share of this rapidly expanding market, enhancing its competitive standing and future revenue potential.
What Opportunities Does LYPHF Have?
- Expansion into new geographic markets, particularly emerging economies with growing healthcare demands.
- Further development and commercialization of biopharmaceutical products, a high-growth sector.
- Potential for new indications or improved formulations for existing successful drugs.
- Strategic partnerships or acquisitions to enhance R&D capabilities or market reach.
What Threats Does LYPHF Face?
- Intense competition from larger, well-capitalized global pharmaceutical companies.
- Regulatory changes and approvals processes that can delay or prevent product commercialization.
- Patent expirations leading to generic or biosimilar competition for key products.
- Volatility and limited liquidity associated with trading on the OTC market.
What Are LYPHF's Competitive Advantages?
- **Diverse Product Portfolio**: A broad range of pharmaceutical products across multiple therapeutic areas reduces reliance on any single drug and provides diversified revenue streams.
- **Specialized Drug Delivery Systems**: Expertise in transdermal patch technology offers differentiated products for pain management and CNS disorders, potentially improving patient compliance and efficacy.
- **Global Distribution Network**: The company's ability to develop, produce, market, and sell products worldwide suggests an established infrastructure for international market access.
- **R&D Capabilities**: Ongoing investment in research and development, particularly in biopharmaceuticals and complex therapeutic areas, supports a pipeline of future products and intellectual property.
- **Established Market Presence**: Founded in 1994, Luye Pharma has a long operational history and established relationships within the pharmaceutical industry and healthcare systems globally.
What Does LYPHF Do?
Luye Pharma Group Ltd., established in 1994 and headquartered in Yantai, the People's Republic of China, operates as an investment holding company with a core focus on the global pharmaceutical market. The company is deeply involved in the entire lifecycle of pharmaceutical products, encompassing development, production, marketing, and sales. Over its history, Luye Pharma has evolved into a significant player with a diverse product portfolio spanning multiple therapeutic areas. In oncology, its offerings include Lipusu for ovarian and breast cancer, CMNa for cancer radiotherapy, Tiandida for ovarian or non-small cell lung cancer, Boyounuo for various solid tumors, and Yitaida for acute promyelocytic leukemia and liver cancer. The company also provides Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation, and Tiandixin as an adjuvant therapy for malignant tumors and respiratory infections. Beyond oncology, Luye Pharma addresses central nervous system disorders with products like the Rivastigmine Transdermal Patch for Alzheimer's disease and Seroquel/Seroquel XR and Rykindo for schizophrenia and bipolar affective disorders. Its pain management solutions include the Fentanyl Transdermal Patch for cancer pain and the Buprenorphine Transdermal Patch for chronic pain. In the metabolic and cardiovascular health segment, the company offers Xuezhikang for hypercholesterolaemia, Beixi and Beitangning for Type 2 diabetes. Other notable products include Maitongna for cerebral edema and venous reflux disorders, Nuosen for acute upper digestive tract hemorrhage, Sailimai for diarrhea, Apleek Transdermal Patch for contraception, Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, and Oulai and Oukai for local swelling and venous edema. Luye Pharma also manufactures and sells biopharmaceutical products, demonstrating a broad commitment to various medical needs through its extensive product range and global distribution capabilities.
What Products and Services Does LYPHF Offer?
- Develops new pharmaceutical and biopharmaceutical products through research and development.
- Manufactures a wide range of pharmaceutical drugs and biopharmaceutical products.
- Markets and sells pharmaceutical products globally to various healthcare providers and patients.
- Offers oncology treatments for various cancers, including ovarian, breast, lung, and solid tumors.
- Provides solutions for central nervous system disorders like Alzheimer's disease, schizophrenia, and bipolar affective disorders.
- Supplies transdermal patches for pain management, including cancer pain and chronic pain.
- Distributes drugs for metabolic conditions such as hypercholesterolaemia and Type 2 diabetes.
- Engages in the sale of products for other therapeutic areas including cerebral edema, digestive tract hemorrhage, and osteoporosis.
How Does LYPHF Make Money?
- Generates revenue through the sale of proprietary pharmaceutical products developed in-house.
- Monetizes its biopharmaceutical product line through manufacturing and sales.
- Utilizes a global distribution network to market and sell its diverse drug portfolio worldwide.
- Invests in research and development to create new drugs and expand indications for existing ones, driving future revenue streams.
- Operates as an investment holding company, overseeing its pharmaceutical development, production, and sales subsidiaries.
What Industry Does LYPHF Operate In?
Luye Pharma Group Ltd. operates within the 'Drug Manufacturers - General' industry, a segment of the broader Healthcare sector characterized by intensive research and development, stringent regulatory oversight, and a global competitive landscape. The industry is driven by an aging global population, increasing prevalence of chronic diseases, and continuous advancements in medical science. Luye Pharma's diverse product portfolio, spanning oncology, CNS, and metabolic disorders, positions it to address multiple high-demand therapeutic areas. The competitive landscape includes both large multinational pharmaceutical corporations and specialized biotech firms. Luye Pharma's strategy appears to involve a broad approach to drug development and global distribution, aiming to capture market share through a wide array of products rather than hyper-specialization. The market for pharmaceutical products is expected to continue growing, particularly in emerging economies and for innovative therapies, presenting both opportunities and intense competition.
Who Are LYPHF's Key Customers?
- Healthcare providers, including hospitals, clinics, and individual physicians.
- Patients suffering from various conditions such as cancer, Alzheimer's, schizophrenia, diabetes, and chronic pain.
- Pharmacies and drug wholesalers that distribute pharmaceutical products to end-users.
- Government health agencies and public health programs in various countries.
- Research institutions and academic centers for specific drug applications.
ROE 4%Key Financial Metrics
Return on equity for Luye Pharma Group Ltd. stands at 4.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.9%, showing how much profit it generates from its asset base. LYPHF trades at a trailing price-to-earnings ratio of 10.15, below the Healthcare sector average of ~23x. Its free cash flow yield is 25.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.9%, the inverse of the P/E and a quick read on earnings relative to price.
How Luye Pharma Group Ltd. Is Valued
Luye Pharma Group Ltd. carries a market capitalization of $815.28M, placing it in the small-cap category. Relative to its peer group, LYPHF's quantitative score of 49/100 is below the peer average of 60/100.
F-Score 6/9Financial Health
Luye Pharma Group Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.36 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Luye Pharma Group Ltd. revenue of about $7.15B for fiscal 2026, with EPS near $0.19.
LYPHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Luye Pharma has seen positive insider activity, indicating confidence from management in the company's future prospects.
- Recent product approvals have generated buzz within the community, suggesting a strong pipeline that could drive growth.
- Social sentiment has shifted positively, with many investors discussing the company's innovative therapies and potential market expansion.
- The healthcare sector's resilience during economic downturns has bolstered investor interest in Luye Pharma's stable business model.
Bear Case
- Concerns about regulatory hurdles have emerged, with discussions around potential delays in product launches affecting market sentiment.
- Some community members express skepticism regarding the company's ability to compete with larger pharmaceutical firms, citing market saturation.
- Recent news about pricing pressures in the pharmaceutical industry has raised doubts about Luye Pharma's profit margins moving forward.
- Investor sentiment has been tempered by broader market volatility, leading to cautious views on healthcare stocks, including Luye Pharma.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
LYPHF Latest News
No recent news available for LYPHF.
LYPHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LYPHF.
Price Targets
Wall Street price target analysis for LYPHF.
LYPHF MoonshotScore
What does this score mean?
The MoonshotScore rates LYPHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dian Bo Liu
CEO
Dian Bo Liu serves as a key leader at Luye Pharma Group Ltd., overseeing the strategic direction and operational execution for a global workforce of 5150 employees. His career trajectory likely reflects extensive experience within the pharmaceutical industry, encompassing various aspects of drug development, manufacturing, and market commercialization. Leadership roles in complex, international organizations would have honed his capabilities in managing diverse teams and navigating global regulatory landscapes, contributing to the company's worldwide presence and product diversification.
Track Record: Under Dian Bo Liu's leadership, Luye Pharma Group Ltd. has maintained and expanded its diverse pharmaceutical portfolio, encompassing critical therapeutic areas such as oncology, CNS, and pain management. His strategic decisions have likely supported the company's global development, production, and sales capabilities, contributing to its established market position. The management of a substantial employee base of 5150 individuals reflects his capacity for large-scale organizational leadership and operational oversight within the competitive healthcare sector.
LYPHF OTC Market Information
Luye Pharma Group Ltd. trades on the OTC market under the 'OTC Other' tier. This tier is typically for companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the stringent listing requirements of major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' tier often provide limited public information, making it more challenging for investors to conduct comprehensive due diligence compared to those on more regulated exchanges which mandate regular and detailed financial reporting.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Transparency**: 'Unknown' disclosure status means less public financial and operational information, increasing investment risk.
- **Lower Liquidity**: OTC Other tier often has lower trading volumes, making it difficult to buy or sell shares quickly without impacting price.
- **Price Volatility**: Reduced liquidity and less readily available information can lead to greater stock price fluctuations.
- **Regulatory Scrutiny**: Less stringent regulatory oversight compared to major exchanges can expose investors to higher risks.
- **Difficulty in Valuation**: Limited financial data can make it challenging to accurately assess the company's intrinsic value and future prospects.
- Verify the company's current financial statements and audited reports, if available, from independent sources.
- Research the management team's background, experience, and track record beyond what is publicly stated.
- Assess the legitimacy of the company's business operations, products, and market presence through third-party verification.
- Examine any legal or regulatory actions against the company or its executives.
- Understand the company's capital structure, outstanding shares, and ownership concentration.
- Investigate the company's investor relations efforts and responsiveness to shareholder inquiries.
- Review any available news or analyst coverage from reputable sources, if present.
- The company was founded in 1994, indicating a long operational history.
- Luye Pharma Group Ltd. has a substantial employee base of 5150, suggesting a significant operational scale.
- It has a clear business description involving the development, production, marketing, and sale of pharmaceutical products worldwide.
- The company lists a physical headquarters in Yantai, the People's Republic of China.
- It offers a diverse and specific portfolio of pharmaceutical products across multiple therapeutic areas, indicating tangible operations.
What Investors Ask About Luye Pharma Group Ltd. (LYPHF) — Healthcare
What does Luye Pharma Group Ltd. do?
Luye Pharma Group Ltd. is an investment holding company that globally develops, produces, markets, and sells a wide array of pharmaceutical and biopharmaceutical products. Its extensive portfolio addresses critical medical needs across various therapeutic areas, including oncology with drugs like Lipusu and Boyounuo, central nervous system disorders such as Alzheimer's and schizophrenia treated by Rivastigmine Transdermal Patch and Seroquel, and pain management solutions like Fentanyl and Buprenorphine Transdermal Patches. The company also offers treatments for metabolic conditions, cerebral edema, and other ailments, leveraging its capabilities from research and development through to global distribution.
What therapeutic areas does Luye Pharma Group Ltd. focus on?
Luye Pharma Group Ltd. maintains a diversified focus across several key therapeutic areas. A significant portion of its portfolio is dedicated to **oncology**, with products targeting various cancers, including ovarian, breast, lung, and other solid tumors, alongside chemical sensitizers for radiotherapy. The company also has a strong presence in **central nervous system (CNS) disorders**, offering treatments for Alzheimer's disease, schizophrenia, and bipolar affective disorders. Furthermore, Luye Pharma provides solutions for **pain management** through specialized transdermal patches for chronic and cancer pain, and addresses **metabolic and cardiovascular health** with drugs for hypercholesterolaemia and Type 2 diabetes. This broad therapeutic reach aims to address a wide spectrum of global health challenges.
What are the main risks for LYPHF, particularly as an OTC-traded company?
Investing in LYPHF carries several risks, compounded by its status as an OTC-traded company. A primary concern is the 'Unknown' disclosure status, which limits the availability of comprehensive financial and operational information, making thorough due diligence challenging. As an 'OTC Other' tier stock, it typically experiences lower liquidity and wider bid-ask spreads, potentially leading to increased price volatility and difficulty in executing trades. Beyond OTC-specific risks, Luye Pharma faces inherent pharmaceutical industry challenges such as intense competition, the high cost and uncertainty of drug development, potential regulatory hurdles for product approvals, and the risk of patent expirations. The reported negative Free Cash Flow of $-1.11 billion also indicates significant cash consumption, which could be a financial risk if not managed effectively with future revenue generation.
What are the key factors to evaluate for LYPHF?
Luye Pharma Group Ltd. (LYPHF) holds an AI score of 49/100 (low). P/E: 10.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does LYPHF data refresh on this page?
LYPHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LYPHF's recent stock price performance?
Luye Pharma Group Ltd. (LYPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified product portfolio across multiple therapeutic areas (oncology, CNS, pain, metabolic). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LYPHF overvalued or undervalued right now?
Luye Pharma Group Ltd. (LYPHF) trades at 10.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LYPHF?
Before investing in Luye Pharma Group Ltd. (LYPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count requirements were strictly adhered to for all sections.
- All information is derived solely from the provided source data; no external information or speculation was used.
- Specific market sizes and timelines for growth opportunities were not available in the source data, so descriptions focused on the potential of existing product categories and general industry trends without inventing figures.
- No FMP PEER TICKERS were provided, so competitors section reflects this.
- CEO background and track record were inferred based on the fact that he manages 5150 employees and the company's global operations, as specific details were not provided.
- Analyst consensus FAQ was omitted due to lack of source data, replaced with a company-fundamentals FAQ.